Jeff L. White

Jeff has been recognized as a leader in the antitrust space by numerous publications including Who’s Who Legal, Law 360, Global Competition Review, Super Lawyers, Euromoney, Legal500 who named Jeff a “Leading Lawyer” for merger control, and by Lawdragon who named him to their “Leading Litigators in America” guide. The guide honors “all-star litigators” from across the U.S. who specialize in an array of litigation matters with “decades of experience on their feet in leading roles in state or federal courts and before government agencies.” Jeff was also shortlisted for Managing Partner of the Year by The National Law Journal. In 2024, he served as lead partner on a deal that was named European Digital Deal of the Year by London Stock Exchange’s Project Finance International Group. His clients describe him as an advisor who is “beyond excellent.” Jeff was previously honored with the Burton Award for Legal Achievement for co-authoring a highly-publicized article on private equity investment in Antitrust, an American Bar Association publication.

Jeff is an active member of the antitrust bar. For several years he served as Vice Chair of the American Bar Association Antitrust Section’s Health Care and Pharmaceuticals Committee and the Executive Editor for the Committee’s quarterly publication, the Antitrust Health Care Chronicle. He also served as Vice Chair and editorial board member of Antitrust, the Antitrust Section’s premier magazine devoted exclusively to antitrust and consumer protection. He has also published a number of articles and other papers on antitrust law developments and actively participates in speaking engagements. He devotes time to pro bono work for the D.C. community, assisting the Washington Legal Clinic for the Homeless and aiding other local organizations.

Key Representations:

• Serving as global antitrust counsel for Brookfield Asset Management and affiliates, one of the world’s largest alternative investment management companies. His recent notable representations for Brookfield include, among numerous others:
• The $1.5 billion pending acquisition of joint control of Castlelake, a global alternative investment firm specializing in asset-based private credit including aviation and specialty finance.
• The $775 million acquisition of data center provider Cyxtera.
• The $7.9 billion sale of Westinghouse Electric Company, a global leader in technologies and services to the nuclear power industry, by Brookfield Business Partners to a consortium involving Brookfield Renewable Partners and Cameco Corporation.
• The $16 billion acquisition of Nielsen Holdings plc, a leading third-party audience measurement, data and analytics company, in partnership with other investors.
• The $8.3 billion acquisition of CDK Global Inc., a leading provider of technology services and software solutions to the automotive industry.
• The $3.5 billion sale of Student Roost, the owner/operator of ~23,000 student housing units across the UK.
• The $14.8 billion acquisition of a 51% stake of GD Towers, a leading European tower company that owns and operates over 40,000 mobile sites across Germany and Austria, from Deutsche Telekom.
• The $1 billion acquisition of Scout Clean Energy, a US-based renewable energy developer and asset management company.
• The ~$4.8 billion acquisition of a 61.2% stake in Oaktree Capital Group, LLC.
• Represented Alpek, an ALFA subsidiary and leading global chemical manufacturing company based in Mexico, in its $620 million acquisition of OCTAL Holding SAOC.
• Represented Maxim Integrated Products, Inc., a designer, developer and manufacturer of integrated circuits, in its $27.5 billion sale to Analog Devices, Inc., a designer, manufacturer and marketer of integrated circuits used in analog and digital signal processing, in a transaction that values the combined enterprise at over $68 billion. Weil served as global antitrust counsel and obtained unconditional clearance for Maxim in one of the largest and most complex antitrust deals of 2020.
• Represented Micron Technology, Inc., a major global supplier of advanced semiconductor systems, in the sale of its Lehi, UT fab, a semiconductor factory, to Texas Instruments, Inc. for $900 million in cash. The transaction closed subject to customary closing conditions.
• Represented Goldman Sachs in its acquisition of NextCapital Group, Inc.
• Represented Genstar Capital in its acquisition of Marcone Supply, Professional Plumbing Group, and Munch’s Supply.
• Advised American Securities and its portfolio company, Emerald Kalama Chemical, LLC, a manufacturer and supplier of food and beverage preservatives, flavor and fragrance intermediates, and other additives, in the antitrust aspects of Emerald’s $1.1 billion sale to LANXESS AG (Germany), a developer, manufacturer and marketer of chemical intermediates, additives, specialty chemicals and plastics.
• Represented Alfa S.A.B. de C.V. in the formation of Corpus Christi Polymers LLC (CCP), a joint venture among industry participants, and CCP’s $1.1 billion acquisition of an under-construction PET-PTA production facility in Corpus Christi, TX from M&G USA Corp. The U.S. Federal Trade Commission conducted an in-depth investigation of the proposed transaction before agreeing to clear the deal subject to conditions in a consent decree. This was a cross-border matter that received unconditional clearance in China, Germany and South Korea. Prior representations of Alfa have included acquisitions of the PET resins business of Wellman, Inc., and the PTA/PET resins business of Eastman Chemicals Company.
• Represented DAK Americas, LLC, (a subsidiary of Alpek, S.A.B. de C.V. (a subsidiary of Alfa, S.A.B. de C.V.)), a leading producer of PET resins and fibers, in its acquisition of a PET recycling facility in Reading, PA having an annual production capacity of 90 million pounds of food-grade rPET pellets, from CarbonLITE P, LLC, and CarbonLITE Holdings LLC.
• Secured a dismissal of all claims for Simon & Schuster in connection with the ebooks and print books litigations involving Amazon, HarperCollins Publishers, Hachette Book Group, Penguin Random House and Macmillan. Plaintiffs generally allege that Amazon and the aforementioned major publishers conspired into agreements that had an effect of inflating wholesale print book prices and the retail price of ebooks. Plaintiffs subsequently filed a second amended complaint, which is at the dismissal stage.
• Represented a leading television broadcaster in an investigation by the U.S. Department of Justice alleging that broadcasters unlawfully shared revenue pacing information and negotiation of a consent decree to resolve and settle the DOJ Antitrust Division’s claims.
• Represented Legg Mason, Inc., a provider of investment management and related services to institutional and individual clients, company-sponsored mutual fuds and other pooled investment vehicles, in its $6.5 billion sale to Franklin Resources, Inc. (o/a Franklin Templeton Investments), a provider of global and domestic investment management to retail, institutional and sovereign wealth clients in, at the time, over 170 countries.
• Represented Canon Inc. in connection with a multi-year HSR Act investigation by the U.S. Department of Justice and U.S. Federal Trade Commission into the transaction structure used in its $6.1 billion acquisition of Toshiba Medical Systems Corporation from Toshiba Corp.
• Represented Allergan plc, a leading global pharmaceutical company, in the $39 billion sale of its global generic pharmaceuticals business to Teva Pharmaceutical Industries Ltd. (“Merger Control Matter of the Year” for the Americas, Global Competition Review Awards 2017).
• Represented AbbVie, a global biopharmaceutical company, in its acquisition of Pharmacyclics, Inc., a transaction valued at $21 billion and which closed without the U.S. Federal Trade Commission issuing a Second Request, as well as its $5.8 billion acquisition of Stemcentrx.
• Represented Walgreens Boots Alliance in its acquisition of 1,932 Rite Aid stores and related assets, a transaction valued at $4.377 billion.
• Represented Walgreens Boots Alliance in its $1.4 billion acquisition (as a minority investor) of PharMerica Corporation, a national provider of institutional pharmacy, specialty infusion and hospital pharmacy management services.
• Represented Thomson Reuters in its $170 million sale of Portia, a portfolio accounting and performance management platform, to SS&C Technologies. Clearance was obtained without a Second Request.
• Represented Reuters Group PLC in its $17.2 billion combination with The Thomson Corporation. Regulatory clearance was successfully obtained from the Antitrust Division of the U.S. Department of Justice after the parties agreed to sell copies of certain databases.
• Represented Bluegrass Materials Company and its controlling shareholder, private equity firm Lindsay Goldberg, in its $1.625 billion sale to Martin Marietta Materials, Inc. Following an in-depth review the deal, the U.S. Department of Justice granted clearance after the parties agreed to a consent order that resolved the DOJ’s competition concerns.
• Represented Providence Equity Partners in a private nationwide antitrust class action lawsuit asserting broad ranging antitrust conspiracy claims against Providence and other private equity firms in connection with multi billion dollar leveraged buyouts dating back to 2003.
• Represented Simon & Schuster in a high-profile series of private antitrust class actions and government investigations into the pricing of e-books, as well as a putative antitrust class action regarding digital rights management software.
• Representing Straight Path Communications in its $3.1 billion sale to Verizon.
• Represented Metaldyne Performance Group in its $3.3 billion sale to American Axle & Manufacturing.
• Represented Arca Continental S.A.B. de C.V. in a multibillion-dollar bottling and distribution joint venture with Coca Cola Co.
• Represented OMERS/DTI in its $1 billion acquisition of Epiq Systems.
• Represented Busch Vacuum in its proposed $1 billion takeover of Pfeiffer Vacuum.
• Represented a major global provider of medical devices, pharmaceuticals, and consumer goods in various high profile acquisitions.